A multicenter, randomized, double-blind, flexible-dose study showed that 3 times as many patients with social anxiety disorder achieved remission while taking Paxil CR, compared with those taking placebo. The study, published in the Journal of Clinical Psychiatry, also showed that patients had a significantly reduced score on the Liebowitz Social Anxiety Scale, as well as on Fear or Anxiety and Avoidance subscales. Paxil CR is the first and only controlled-release selective serotonin reuptake inhibitor indicated for social anxiety disorder, the most common type of anxiety disorder. Paxil CR also is indicated for treating depression, panic disorder, and premenstrual dysphoric disorder.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs